Literature DB >> 34481797

Psychoactive Substance Use Among Individuals With Chronic Spinal Cord Injury: Patterns and Characteristics.

Nicole D DiPiro1, James S Krause2.   

Abstract

OBJECTIVE: To identify the patterns of nonprescription psychoactive substance (PAS) use among persons with spinal cord injury (SCI) and the relationships with demographic and injury characteristics.
DESIGN: Cross-sectional, self-report assessment (SRA).
SETTING: A medical university in the southeastern United States. PARTICIPANTS: The participants (N=4670) were identified through a specialty hospital and 2 state-based surveillance registries.
INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Participants completed SRAs and reported the past 3 months' use of the following substances for which they did not have a prescription: cannabis, cocaine, amphetamine-type stimulants, inhalants, sedatives/hypnotics and sleeping pills, hallucinogens, and opioids. PAS use was grouped into 4 categories: none, cannabis use only, use of cannabis and other PAS, and use of other PAS only.
RESULTS: Of the 4577 participants who responded to the PAS use questions, 24.1% reported using at least 1 PAS without a prescription. Cannabis was the most frequently reported substance (16.4%), followed by sedatives or sleeping pills (8.0%). By PAS use group, 12.1% reported use of cannabis use only, followed by use of other PAS only (7.7%) and use of cannabis and other PAS (4.3%). There were significant differences among the groups of use by nearly all personal characteristics.
CONCLUSIONS: The use of nonprescription PASs is prevalent among adults with chronic SCI, and there are clear differences in patterns and characteristics of use.
Copyright © 2021 The American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Illicit drugs; Psychotropic drugs; Rehabilitation; Spinal cord injuries

Mesh:

Substances:

Year:  2021        PMID: 34481797      PMCID: PMC9202538          DOI: 10.1016/j.apmr.2021.08.005

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   4.060


  9 in total

Review 1.  Substance misuse in individuals with spinal cord injury.

Authors:  C L Radnitz; D Tirch
Journal:  Int J Addict       Date:  1995-07

2.  Substance use and receipt of treatment by persons with long-term spinal cord injuries.

Authors:  A W Heinemann; M D Doll; K J Armstrong; S Schnoll; G M Yarkony
Journal:  Arch Phys Med Rehabil       Date:  1991-06       Impact factor: 3.966

3.  Survey of alcohol and drug misuse in spinal cord injured veterans.

Authors:  V R Kirubakaran; V N Kumar; B J Powell; A J Tyler; P J Armatas
Journal:  J Stud Alcohol       Date:  1986-05

4.  Behavioral Factors and Unintentional Injuries After Spinal Cord Injury.

Authors:  Yue Cao; Nicole DiPiro; Chao Li; Jon Roesler; James S Krause
Journal:  Arch Phys Med Rehabil       Date:  2019-10-10       Impact factor: 3.966

Review 5.  Use of psychoactive substances in persons with spinal cord injury: a literature review.

Authors:  M Tétrault; F Courtois
Journal:  Ann Phys Rehabil Med       Date:  2014-10-22

6.  Patterns of alcohol and substance use and abuse in persons with spinal cord injury: risk factors and correlates.

Authors:  Denise G Tate; Martin B Forchheimer; James S Krause; Michelle A Meade; Charles H Bombardier
Journal:  Arch Phys Med Rehabil       Date:  2004-11       Impact factor: 3.966

7.  Alcohol and marijuana use in a community-based sample of persons with spinal cord injury.

Authors:  M E Young; D H Rintala; C D Rossi; K A Hart; M J Fuhrer
Journal:  Arch Phys Med Rehabil       Date:  1995-06       Impact factor: 3.966

8.  Drug use and abuse in an urban veteran spinal cord injured population.

Authors:  J L Rothstein; E Levy; R Fecher; S K Gordon; W A Bauman
Journal:  J Am Paraplegia Soc       Date:  1992-10

9.  The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility.

Authors: 
Journal:  Addiction       Date:  2002-09       Impact factor: 6.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.